Medtronic plc
Medtronic plc is classed by the SEC under Electromedical & Electrotherapeutic Apparatus (industry code 3845), based in Galway. In its latest annual figures on file, for the fiscal year ended 2026-04-24, it reported revenue of $36 billion and a profit of $4.8 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3845, Electromedical & Electrotherapeutic Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.3 out of ten, 9 of 9 metrics filed: past 7.1 out of ten, present 6.6 out of ten, future 5.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2017. 80th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 5.7 out of ten. +2.3% a year over 10 filed years; profitable in 10 of 10. 57th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 8.6 out of ten. Share count shrank 1.1% a year. 82% of cash flow returned. Insiders: 16 sales, 0 purchases. 86th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.5 out of ten. ROE 10%: 10¢ of profit per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar. 65th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.2 out of ten. top 28% of 24 in its family; net margin 13.2%. 72nd percentile among 24 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 6.0 out of ten. top 40% of 19 in its family for leadership; chief executive since 2020. 60th percentile among 19 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.9 out of ten. bottom 49% of 23 in its family for room to expand. 49th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.4 out of ten. top 46% of 25 in its family for growth drivers. 54th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.0 out of ten. bottom 50% of 20 in its family for expectations against reality. 50th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-06-18 for the period ended 2026-04-24 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-09-03 for the period ended 2026-07-31 (on EDGAR). Newest results release: Form 8-K filed 2026-09-01 (on EDGAR). Newest filing: Form 425, 2026-10-09. Filings on record since 2014. Read from EDGAR 2026-10-12.
Where the revenue comes from
By geography: Rest of world 50%, United States 50%, Ireland under 1%. As tagged in its annual report (Form 10-K, filed 2026-06-18).
Who runs it
Martha, Geoffrey (Chairman and CEO); Kiil, Harry Skip (EVP & President Cardiovascular); Thompson, Kweli (EVP & President, Neuroscience); Pieton, Thierry (EVP & Chief Financial Officer); Blomquist, Denise L. (Chief Accounting Officer); Walter, Matthew R. (SVP, Chief HR Officer); Marinaro, Michael (EVP, Pres MedSurg and Americas); Quinn, Michelle (EVP, GC and Secretary); Wall, Brett A. (EVP & Pres Neuroscience); Smith, Gregory L (EVP Global Ops & Supply Chain); and 11 more. 21 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.